Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 438-443

  Mahmud, Salaheddin M ^a,b   Kliewer, Erich V ^a,b,c   Lambert, Pascal ^b   Bozat Emre, Songul ^a   Demers, Alain A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Epidemiology and Cancer Registry   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; WART VIRUS VACCINE;

ADOLESCENT; AGE; ARTICLE; CANADA; CANCER GRADING; CASE CONTROL STUDY; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGRAM EVALUATION; PROPORTIONAL HAZARDS MODEL; REGISTER; TIME; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VACCINATION; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; AGE FACTORS; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MANITOBA; NEOPLASM GRADING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 84897577067     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.4645     Document Type: Article

References (30)

1. Munoz N, Bosch FX, Castellsague X, et al: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278-285, 2004 (Pubitemid 38924707)
2. Garland SM, Steben M, Sings HL, et al: Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199:805-814, 2009
3. Markowitz LE, Tsu V, Deeks SL, et al: Human papillomavirus vaccine introduction: The first five years. Vaccine 30:F139-F148, 2012 (suppl 5)
4. Public Health Agency of Canada: Publicly funded immunization programs in Canada - Routine schedule for infants and children including special programs and catch-up programs (as of December 2012). http://www.phac-aspc.gc.ca/im/ ptimprog-progimpt/table-1-eng.php
5. Lu B, Kumar A, Castellsague X, et al: Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review and meta-analysis. BMC Infect Dis 11:13, 2011
6. FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927, 2007
7. Lehtinen M, Paavonen J, Wheeler CM, et al: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89-99, 2012
8. Paavonen J, Naud P, Salmeron J, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314, 2009
9. Roland M, Torgerson DJ: Understanding controlled trials: What are pragmatic trials? BMJ 316: 285, 1998
10. Franco EL, Mahmud SM, Tota J, et al: The expected impact of HPV vaccination on the accuracy of cervical cancer screening: The need for a paradigm change. Arch Med Res 40:478-485, 2009
11. Brotherton JM, Fridman M, May CL, et al: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 377:2085-2092, 2011
12. Morgenstern H: Ecologic studies in epidemiology: Concepts, principles, and methods. Annu Rev Public Health 16:61-81, 1995
13. Robinson JR, Young TK, Roos LL, et al: Estimating the burden of disease: Comparing administrative data and self-reports. Med Care 35:932-947, 1997 (Pubitemid 127453475)
14. Roos L, Mustard C, Nicol J, et al: Registries and administrative data: Organization and accuracy. Med Care 31:201-212, 1993
15. Mahmud SM, Van Caeseele P, Hammond G, et al: No association between 2008-09 influenza vaccine and influenza A (H1N1) pdm09 virus infection, Manitoba, Canada, 2009. Emerg Infect Dis 18:801-810, 2012
16. Mahmud S, Hammond G, Elliott L, et al: Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case-control study. Vaccine 29: 7975-7981, 2011
17. Roberts J, Roos L, Poffenroth L, et al: Surveillance of vaccine-related adverse events in the first year of life: A Manitoba cohort study. J Clin Epidemiol 49:51, 1996
18. CancerCare Manitoba: 2013 Guidelines for breast, cervical and colorectal cancer screening. http://www.cancercare.mb.ca/resource/File/Screening/2013/CCMB- Screening-Guidelines-2013.pdf
19. Canadian Partnership Against Cancer: The 2011 Cancer System Performance Report. http://www.partnershipagainstcancer.ca/wp-content/uploads/2011-Cancer- System-Performance-Report.pdf.
20. Demers A, Harrison M, Musto G, et al: Cervical Cancer and Pap Test Utilisation in Manitoba, 1970-1999. Winnipeg, Manitoba: Manitoba Cervical Cancer Screening Program, Cancer Care Manitoba, 2004
21. Kliewer EV, Demers AA, Brisson M, et al: The Manitoba human papillomavirus vaccine surveillance and evaluation system. Health Rep 21:37, 2010
22. Roberts J, Poffenroth L, Roos L, et al: Monitoring childhood immunizations: A Canadian approach. Am J Public Health 84:1666, 1994
23. Read TR, Hocking JS, Chen MY, et al: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87:544-547, 2011
24. Donovan B, Franklin N, Guy R, et al: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect Dis 11:39-44, 2011
25. Baandrup L, Blomberg M, Dehlendorff C, et al: Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 40:130-135, 2013
26. Mikolajczyk RT, Kraut AA, Horn J, et al: Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany: An ecologic study. Sex Transm Dis 40:28-31, 2013
27. Tabrizi SN, Brotherton JML, Kaldor JM, et al: Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206:1645-1651, 2012
28. Smith JS, Lindsay L, Hoots B, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121:621-632, 2007 (Pubitemid 46986496)
29. Kjaer SK, Sigurdsson K, Iversen O-E, et al: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Preven Res 2:868-878, 2009
30. Shrank WH, Patrick AR, Alan Brookhart M: Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med:1-5, 2010